Acting FDA Commissioner Ned Sharpless told agency staff in an email Tuesday (July 23) that his top priorities are to develop frameworks for regulating new technologies; invest in the agency’s workforce; help to lower drug prices by encouraging drug competition; and improve postmarket surveillance of regulated products. A former FDA staffer said the priority list echoes those of previous commissioners, but the emphasis on hiring reform could signal that the agency is prepared to tap into its excess user fees...